WO2024003787 - COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES WITH DIABETES
National phase entry is expected:
Publication Number
WO/2024/003787
Publication Date
04.01.2024
International Application No.
PCT/IB2023/056716
International Filing Date
28.06.2023
Title **
[English]
COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES WITH DIABETES
[French]
COMPOSITIONS ET MÉTHODES DE PRÉVENTION ET DE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES CONCOMITANTES AU DIABÈTE
Applicants **
ARIBIO CO., LTD.
56, Dongpangyo-ro, Bundang-gu
Seongnam-si
Gyeonggi-do 13535, KR
Inventors
CHOUNG, Jai Jun
234 Hwangsaeul-ro 229 ho, Bundang-gu
Seongnam-si
Gyeonggi-do, KR
Priority Data
63/367,278
29.06.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
MOIP
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1206 | |
| EPO | Filing, Examination | 7670 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 10510 |
Total: 20550 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention provides a composition for preventing or treating a neurodegenerative disease containing a phosphodiesterase-5 (PDE-5) inhibitor and an anti-diabetic therapeutic including sodium-glucose cotransporter 2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (PPD-4) inhibitor and a method using thereof, wherein the PDE5 inhibitor is selected from among mirodenafil, sildenafil, vardenafil, tadalafil, udenafil, dasantafil, avanafil, pharmaceutically acceptable salts, solvates, hydrates, and a mixture thereof; and the SGLT2 inhibitor is selected from among canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, tofogliflozin, remogliflozin etabonate, sergliflozin etabonate, pharmaceutically acceptable salts, solvates, hydrates and a mixture thereof; and the neurodegenerative disease is selected from the group among dementia, Parkinson's disease (PD), Dementia with Lewy body (DEB), Alzheimer's disease (AD), Huntington's disease (HD), Multiple sclerosis (MS), Vascular Dementia (VaD), Amyotrophic Lateral Sclerosis (AES), frontotemporal dementia, or a mixed etiologies thereof.[French]
La présente invention concerne une composition pour prévenir ou traiter une maladie neurodégénérative contenant un inhibiteur de phosphodiestérase-5 (PDE-5) et un agent thérapeutique antidiabétique comprenant un inhibiteur du cotransporteur de sodium-glucose 2 (SGLT2) et un inhibiteur de la dipeptidyl peptidase-4 (PPD-4) et une méthode l'utilisant, l'inhibiteur de PDE5 étant choisi parmi le mirodénafil, le sildénafil, le vardénafil, le tadalafil, l'udénafil, le dasantafil, l'avanafil, les sels, solvates, hydrates pharmaceutiquement acceptables, et un mélange de ceux-ci; et l'inhibiteur de SGLT2 étant choisi parmi la canagliflozine, la dapagliflozine, l'empagliflozine, l'ertugliflozine, l'ipragliflozine, la luséogliflozine, la tofogliflozine, l'étabonate de rémogliflozine, l'étabonate de sergliflozine, des sels, solvates, hydrates pharmaceutiquement acceptables et un mélange de ceux-ci; et la maladie neurodégénérative étant choisie dans le groupe parmi la démence, la maladie de Parkinson (MP), la démence à corps de Lewy (DCL), la maladie d'Alzheimer (MA), la maladie de Huntington (MH), la sclérose en plaques (SEP), la démence vasculaire (DVa), la sclérose latérale amyotrophique (SLA), la démence frontotemporale, ou des étiologies mixtes de celles-ci.